ea0020p108 | Thyroid | ECE2009
David Taieb
, Frederic Sebag
, Maria Cherenko
, Karine Baumstarck-Barrau
, Farman-Ara Bardia
, De Micco Catherine
, Henry Jean Francois
, Mundler Olivier
Background: Recombinant human TSH (rhTSH) has become the modality of choice for radioiodine remnant ablation of residual thyroid cancer tissue in low-risk patients.Methods: The FACIT-F was administered from the early postoperative period to 9 months. Socio-demographic parameters, anxiety and depression scales were also evaluated. At 24 h, 48 h and d6 post-therapy, dose rate were measured. Using a simplified model, radiation exposure to public was estimat...